Dupixent (dupilumab) prior authorization denied appeal
IL-4/13 inhibitor
Typical PA criteria
- Moderate-to-severe atopic dermatitis, asthma, CRSwNP, EoE, or prurigo nodularis
- Trial of topical or inhaled therapy
- Specialist prescriber
Why your PA was denied
- Topical or inhaled therapy trial not documented
- Severity not documented
- Off-label indication
Evidence that overturns the denial
- ✓EASI or IGA scores for AD
- ✓FEV1, eosinophil count, exacerbation history for asthma
- ✓Prior therapy log
- ✓Specialist letter
Severity documentation is the most common gap; quantify it before appealing.
Free analysis identifies the cited policy and missing evidence. Then a finished letter that maps your chart to the criteria.
FAQ
Why was my Dupixent (dupilumab) prior authorization denied?+
The most common reasons are: Topical or inhaled therapy trial not documented; Severity not documented; Off-label indication. Your denial letter names the specific criteria you did not meet.
How do I appeal a Dupixent (dupilumab) denial?+
File a written appeal within 180 days that cites the insurer's clinical policy, includes a letter of medical necessity from the prescriber, and documents the criteria the insurer requires.
What evidence overturns a Dupixent (dupilumab) denial?+
EASI or IGA scores for AD; FEV1, eosinophil count, exacerbation history for asthma; Prior therapy log.
What if the plan excludes Dupixent (dupilumab) entirely?+
Plan exclusions are different from medical-necessity denials. Check the Summary Plan Description. If the drug is fully excluded, an appeal will not overturn it; you may need a formulary exception or manufacturer assistance program.
Other drugs
- Wegovy (semaglutide)
- Zepbound (tirzepatide)
- Ozempic (semaglutide)
- Mounjaro (tirzepatide)
- Saxenda (liraglutide)